Skip to main content

Table 1 General characteristics of the study patients

From: Missed radiation therapy sessions in first three weeks predict distant metastasis and less favorable outcomes in surgically treated patients with oral cavity squamous cell carcinoma

  RT as scheduled Late missed RT Early missed RT Entire cohort p value
Number 448 341 116 905  
Sex, n (%)      0.210
 Women 26 (5.8%) 21 (6.2%) 12 (10.3%) 59 (6.5%)  
 Men 422 (94.2%) 320 (93.8%) 104 (89.7%) 846 (93.5%)  
Age (years), median (range) 50.8 (25.1–89.4) 51.1 (28.0–83.6) 49.8 (25.1–78.8) 50.8 (25.1–89.4) 0.330
Age (years), n (%)      0.481
  < 60 363 (81.0%) 274 (80.4%) 95 (81.9%) 732 (80.9%)  
  ≥ 60 85 (19.0%) 67 (19.6%) 21 (18.1%) 173 (19.1%)  
Differentiation      0.305
 Well differentiated 104 (23.2%) 87 (25.5%) 40 (34.5%) 232 (25.6%)  
 Moderately differentiated 284 (63.4%) 199 (58.4%) 62 (53.5%) 545 (60.2%)  
 Poorly differentiated 60 (13.4%) 55 (16.1%) 14 (12.0%) 128 (14.2%)  
pStage, n (%)      0.710
 Stage I 6 (1.3%) 2 (0.6%) 0 (0%) 8 (0.9%)  
 Stage II 16 (3.6%) 11 (3.2%) 2 (1.7%) 29 (3.2%)  
 Stage III 123 (27.5%) 100 (29.3%) 33 (28.4%) 256 (28.3%)  
 Stage IV 303 (67.6%) 228 (66.9%) 81 (69.8%) 612 (67.6%)  
pT − Stage, n (%)      0.824
 T1/2 58 (12.9%) 40 (11.7%) 16 (13.8%) 114 (12.6%)  
 T3/4 390 (87.1%) 301 (88.3%) 100 (86.2%) 791 (87.4%)  
pN − Stage, n (%)      0.828
 N0/1 255 (56.9%) 198 (58.0%) 63 (54.3%) 516 (57.0%)  
 N2/3 193 (43.1%) 143 (42.0%) 53 (45.7%) 389 (43.0%)  
RTT (days), median (range) 46 (39–53) 49 (44–56) 50 (43–56) 47 (39–56) 0.131
 Mean ± SD 45.6 ± 2.52 49.0 ± 2.77 50.3 ± 2.94 47.5 ± 3.28 0.120
S/RT interval (days), median (range) 39 (15–106) 40 (15–94) 37 (17–77) 39 (15–106) 0.078
 Mean ± SD 40.2 ± 12.2 41.6 ± 13.4 38.4 ± 10.4 40.5 ± 12.5 0.061
S/RT interval (days), n (%)      0.256
  ≤ 42 326 (72.8%) 231 (67.7%) 85 (73.3%) 642 (70.9%)  
  > 42 122 (27.2%) 110 (32.3%) 31 (26.7%) 263 (29.1%)  
TPT (days), median (range) 84 (50–152) 88 (63–143) 86 (65–128) 86 (59–152) 0.058
 Mean ± SD 85.8 ± 12.4 90.5 ± 13.8 88.6 ± 10.7 88.0 ± 12.9 0.029
TPT (days), n (%)      < 0.001
  ≤ 85 254 (56.7%) 133 (39.0%) 49 (42.2%) 436 (48.2%)  
  > 85 194 (43.3%) 208 (61.0%) 67 (57.7%) 469 (51.8%)  
RT techniques      0.691
 2D RT 76 (16.9%) 68 (19.9%) 20 (17.2%) 164 (18.1%)  
 3D conformal RT 43 (9.6%) 14 (4.1%) 12 (10.3%) 69 (7.6%)  
 IMRT 296 (66.1%) 223 (65.4%) 80 (70.0%) 599 (66.2%)  
 VMAT 33 (7.4%) 36 (10.6%) 4 (3.5%) 73 (8.1%)  
Chemotherapy, n (%)      0.933
 Yes 248 (55.4%) 190 (55.7%) 67 (57.8%) 505 (55.8%)  
 No 200 (44.6%) 151 (44.3%) 49 (42.2%) 400 (44.2%)  
PET imaging, n (%)      0.095
 Yes 233 (52.0%) 151 (44.3%) 58 (50.0%) 442 (48.8%)  
 No 215 (48.0%) 190 (55.7%) 58 (50.0%) 463 (51.2%)  
Smoking, n (%)      0.864
 No 65 (14.5%) 46 (13.5%) 18 (15.5%) 129 (14.3%)  
 Yes 383 (85.5%) 295 (86.5%) 98 (84.5%) 776 (85.7%)  
Betel quid chewing, n (%)      0.366
 No 94 (21.0%) 85 (24.9%) 29 (25.0%) 208 (23.0%)  
 Yes 354 (79.0%) 256 (75.1%) 87 (75.0%) 697 (77.0%)  
Alcohol use, n (%)      0.171
 No 182 (40.6%) 116 (34.0%) 43 (37.1%) 341 (37.7%)  
 Yes 266 (59.4%) 225 (66.0%) 73 (62.9%) 564 (62.3%)  
Comorbidities, n (%)      0.227
 No 237 (52.9%) 159 (46.6%) 61 (52.6%) 456 (50.3%)  
 Yes 211 (47.1%) 182 (53.4%) 55 (47.4%) 448 (49.5%)  
  1. Data are given as counts (percentages), means ± standard deviations, or medians (ranges), as appropriate. Abbreviations: RT radiotherapy, RTT radiation treatment time, S surgery, SD standard deviation, TPT treatment package time, 2D two-dimensional, 3D three-dimensional, IMRT intensity-modulated radiation therapy, VMAT volumetric-modulated arc therapy, PET positron emission tomography